<DOC>
	<DOC>NCT02444572</DOC>
	<brief_summary>Comparison of thromboembolic events between Enoxa® and Lovenox® in patients undergoing digestive cancer and subjected to thromboprophylaxis.</brief_summary>
	<brief_title>Comparison of Thromboembolic Events Between Enoxa® and Lovenox® in Patients Undergoing Digestive Cancer</brief_title>
	<detailed_description>Comparative study with two arms versus ENOXA® LOVENOX®, randomized, prospective, single-center, with rater-blinded whose main objective is to compare the incidence of thromboembolic events (symptomatic and asymptomatic) between the two arms of the study, in patients undergoing digestive cancer and receiving thromboprophylaxis based SODIUM enoxaparin.</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>Male or female over 18 years Digestive Cancer proved whatever its nature, its site or stage Surgical indication in emergency or programmed, whatever its nature Preventive administration of enoxaparin sodium Patients participating in another study Impregnation prior to Unfractionated heparin (UFH) in the last 30 days Renal impairment with creatinine clearance &lt;30 ml / min Known history of peripheral venous thrombosis and / or deep occurred in the previous 3 months of study entry Pregnant or breastfeeding women or women of childbearing potential not using medically accepted contraceptive method Taking an anticoagulant in the last three months Patients with known haemostatic disorder No one wishing to participate in this study, or not having the ability to understand its objectives</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>